Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Metabolic & Weight

Liraglutide

NN2211; Saxenda; Victoza

GLP-1 receptor agonist

This Liraglutide entry draws on 63 cited sources published 2015 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
GLP-1 receptor agonist
Drug class
Metabolic & Weight
Structure
31-aa GLP-1 analog with C16 fatty acid; MW ~3751 Da
Route
SC injection
Half-life
~13 hrs
Evidence tier
FDA-Approved
Availability
Prescription
Research depth
321 indexed citations (PubMed 197 · CT 69 · EPMC 55) →

Mechanism of action

GLP-1R agonist; albumin-binding fatty acid extends half-life

Reported areas of research

T2D glycemic control; weight loss ~5-10% (Saxenda); cardiovascular protection

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label)

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning

Compared with

Liraglutide has published head-to-head comparisons with 8 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Liraglutide in research literature?

Published peptide research reports the following dosing approach for Liraglutide: 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label). This is a research reference, not a clinical recommendation.

How is Liraglutide administered in research?

Liraglutide is administered via the following routes in published studies: SC injection.

What is the reported half-life of Liraglutide?

The reported half-life of Liraglutide is ~13 hrs.

Is Liraglutide FDA-approved?

Yes. Liraglutide is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.

What level of evidence supports Liraglutide?

The current evidence base for Liraglutide is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Liraglutide?

Known concerns reported in the literature for Liraglutide include: Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning. Always consult a qualified clinician before any human use.

Is there anyone who should not use Liraglutide?

Yes. The FDA label for Liraglutide lists formal contraindications for Liraglutide: Liraglutide injection is contraindicated in patients with a: personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). serious hypersensitivity reaction to liraglutide or to any of the excipients in liraglutide injection. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with liraglutide injection. Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Patients with a serious hypersensitivity reaction to liraglutide or any of the excipients in liraglutide injection. This is the label's own wording, quoted rather than paraphrased. Always consult a qualified clinician before any human use.

How does Liraglutide work?

The mechanism of action reported for Liraglutide in the literature: GLP-1R agonist; albumin-binding fatty acid extends half-life.

What is Liraglutide studied for?

Liraglutide has been studied in the published literature for: T2D glycemic control; weight loss ~5-10% (Saxenda); cardiovascular protection. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Liraglutide?

Liraglutide is classified as: GLP-1 receptor agonist. Also known as: NN2211; Saxenda; Victoza.

Combinations to avoid

Liraglutide appears in 2 flagged combinations catalogued on PeptideHelper.org:

Drug class

Research focus area

All peptides studied for Metabolic & Weight, ranked by evidence tier and regulatory status.

Primary sources

  1. FDA Saxenda (liraglutide) prescribing information for chronic weight management
  2. FDA Victoza (liraglutide) prescribing information
  3. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). N Engl J Med 2015. PMID 26132939
  4. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016. PMID 27295427
  5. Lewis KH et al. Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications. Obesity (Silver Spring, Md.) 2026. PMID 42120922
  6. Li Y et al. A multi-organ atlas of microcirculatory signatures for systemic profiling of diabetic and therapeutic states. Scientific data 2026. PMID 42120879
  7. Kołakowski A et al. Do GLP-1 receptor agonists improve insulin sensitivity and reduce lipid accumulation in skeletal muscles and the liver independent of weight loss?. Endokrynologia Polska 2026. PMID 42112562
  8. Chen Z et al. AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension. European heart journal 2026. PMID 42517561
  9. Abdollahi S et al. Peptide Hormones in Appetite Regulation: A Complex Network. Pharmaceuticals (Basel, Switzerland) 2026. PMID 42515672
  10. Kim JM et al. Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study. Pharmaceutics 2026. PMID 42514852
  11. Bijoch J. Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies. Journal of clinical medicine 2026. PMID 42513271
  12. Mori Y et al. Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide. Biomedicines 2026. PMID 42512027
  13. Nijakowski K et al. Relationship Between GLP-1-Based Therapies and Periodontal Health: A Systematic Review of Current Evidence and Future Perspectives. International journal of molecular sciences 2026. PMID 42511792
  14. Sheth S et al. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review. JAMA dermatology 2026. PMID 42054048
  15. Vilsbøll T et al. Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide. The British journal of ophthalmology 2026. PMID 42049287
  16. Ho MJ et al. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases. Expert review of clinical immunology 2026. PMID 42043978
  17. Peng T et al. The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study. Diabetes, metabolic syndrome and obesity : targets and therapy 2026. PMID 42094035
  18. Bakken IJ et al. Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study. Diabetes, obesity & metabolism 2026. PMID 42086462
  19. Takashima S et al. Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study. Diabetology international 2026. PMID 42078492
  20. Loblundo C et al. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2026. PMID 42611692
  21. Le Y et al. Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis. Foot & ankle specialist 2026. PMID 42609010
  22. Cipolla S et al. Treatment of obesity with liraglutide in bipolar disorder: a case report. Frontiers in psychiatry 2026. PMID 42597211
  23. Puspitasari IM et al. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review. Diabetes, metabolic syndrome and obesity : targets and therapy 2026. PMID 42812898
  24. Liu X et al. Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing. Investigative ophthalmology & visual science 2026. PMID 42808829
  25. Mera-Carreiro S et al. Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass. Obesity surgery 2026. PMID 42802300
  26. Carson L et al. Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists. Skin health and disease 2026. PMID 42813201
  27. Duan B et al. A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2026. PMID 42762056
  28. Beaudart C et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs 2026. PMID 42730869
  29. Pałka W et al. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. Journal of endocrinological investigation 2026. PMID 42560457
  30. Zhu K et al. Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis. Journal of diabetes investigation 2026. PMID 42549609
  31. Katamine A et al. Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications. Journal of diabetes investigation 2026. PMID 42499272
  32. Province HS et al. Parabrachial CGRP neurons mediate incretin-induced aversion and anti-aversion, but not anorexia or weight loss. Molecular metabolism 2026. PMID 42838450
  33. Tian W et al. Effects of Sitagliptin Combined with GTS-21 on Improving Glycemic Control and Diabetic Nephropathy by Anti-Apoptosis in Leprdb/db Mice. European journal of pharmacology 2026. PMID 42874910
  34. Borschel L et al. Development and validation of qualitative methods for the detection of GLP-1 receptor agonists in serum and dried blood spots by LC-HRMS/MS for doping control purposes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2026. PMID 42874322
  35. Wang P et al. Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation. Journal of molecular histology 2026. PMID 42870021
  36. Wang X et al. Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2026. PMID 42867646
  37. Su F et al. Recovery from liraglutide-induced acute liver injury assessed for causality using the updated RUCAM as global gold standard: A case report and literature review. International journal of clinical pharmacology and therapeutics 2026. PMID 42867191
  38. Rossatto T et al. GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection. Diabetes, obesity & metabolism 2026. PMID 42946972
  39. Le D et al. Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis. Diabetes care 2026. PMID 42937520
  40. Cassano DA et al. Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner. Life sciences 2026. PMID 42933595
  41. Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity [NCT07901777 RECRUITING]
  42. A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics [NCT04466566 PHASE3 COMPLETED]
  43. Loggie J et al. Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature. The American Journal of dermatopathology 2026. PMID 42961329
  44. Hunter K et al. Editorial Expression of Concern: Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC neuroscience 2026. PMID 42958044
  45. Sićović K et al. GLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways. British journal of pharmacology 2026. PMID 42950887
  46. Li W et al. Core-shell hydrogel beads co-encapsulating kunitz-type trypsin inhibitor: A synergistic strategy for enhanced stability of oral active peptides. Food research international (Ottawa, Ont.) 2026. PMID 42637435
  47. A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease [NCT07907965 PHASE2 ACTIVE_NOT_RECRUITING]
  48. Zhou H et al. Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment. Diabetic medicine : a journal of the British Diabetic Association 2026. PMID 42965922
  49. Castano Heredia G et al. Real-world effectiveness of liraglutide in children with type 2 diabetes. Journal of the Endocrine Society 2026. PMID 42936196
  50. Zafar A et al. Liraglutide Dose Affordability and Durability in Real-World Obesity Care. Endocrinology, diabetes & metabolism 2026. PMID 42867112
  51. Abolhassan MR et al. Development of an albumin-binding domain-fused GLP-1 analog: Structural insights, receptor activation, and functional characterization. International journal of biological macromolecules 2026. PMID 42967512
  52. Dong H et al. Oral Janus nanomotor covalent conjugation rapeseed protein-derived DPP-IV inhibitory peptide and liraglutide: A self-propelled targeted delivery system for promoting insulin secretion and glucose-lowering. Food research international (Ottawa, Ont.) 2026. PMID 42692655
  53. Caballero-Corbalán J et al. Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial. Diabetes, obesity & metabolism 2026. PMID 42595732
  54. Ernst C et al. Liraglutide and Semaglutide Induce Nitric Oxide-Dependent Contraction of Larger and Relaxation of Smaller Porcine Retinal Resistance Vessels Ex Vivo. Investigative ophthalmology & visual science 2026. PMID 42975103
  55. The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes [NCT07913685 PHASE4 COMPLETED]
  56. Liu W et al. Corrigendum to "Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease" [Neuroscience 303 (2015) 42-50]. Neuroscience 2026. PMID 42998608
  57. Bilal Azam M et al. Excessive Intrapancreatic Fat Deposition and the Potential Therapeutic Role of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2026. PMID 43008789
  58. Giugliano D et al. GLP-1 receptor agonists for people with type 2 diabetes and peripheral artery disease: reducing uncertainty in clinical practice. Endocrine 2026. PMID 43007383
  59. Silverbeck J et al. Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial. Diabetes, obesity & metabolism 2026. PMID 43003406
  60. GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications [NCT07932119 COMPLETED]
  61. SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity [NCT04775082 PHASE3 ACTIVE_NOT_RECRUITING]
  62. Mengr A et al. Metabolic, Hepatic, and Neuropathological Effects of Palm11-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice. Neuropharmacology 2026. PMID 43039332
  63. Fox CK et al. Obesity in Children Aged 2 to 12 Years: A Review. JAMA 2026. PMID 42905688

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…